Veracyte raised full-year revenue guidance after strong Q1 results, driven by continued volume growth for its Decipher prostate prognostic test and Afirma thyroid cancer classifier. The company reported Q1 revenue of $139.1 million, up 21% year over year, and increased its 2026 revenue range to $582 million–$592 million. Management pointed to upcoming launches of Prosigna LDT and TrueMRD as major drivers for market expansion across breast, bladder, and other cancers. Veracyte also highlighted “growing clinical evidence” supporting its platforms, suggesting its commercialization strategy is increasingly tied to data publication and real-world adoption. For the diagnostics segment, the message is clear: guidance upgrades are being underwritten by both near-term test uptake and a plan for new molecular offerings, rather than only single-test resilience.